We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hea...
Continue reading
Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization ...
Continue reading
We are delighted to have been honoured once again by Managing IP (MIP) as a "Top Tier Firm" in the 2025 IP Stars Patent Ranking. With awards in the categories of "Patent Prose...
Continue reading
For more awards and information, click here.
